Santhera Expands Biomedica Agreement to Extend AGAMREE (Vamorolone) Distribution Across Central Asia and the Caucasus
Santhera today announces an expansion of its exclusive distribution agreement with Biomedica for AGAMREE (vamorolone), extending the partnership to include Georgia, Kazakhstan, Belarus, Azerbaijan...
SAT-3247 Six-Month TRAILHEAD Results Show Reduced Muscle Fat and Lower CK in Adults with Duchenne muscular dystrophy
New six-month interim results from the TRAILHEAD clinical trial suggest that SAT-3247 may help improve muscle health and preserve physical function in adults living...
Satellos Receives FDA Fast Track Designation for SAT-3247 in Duchenne Muscular Dystrophy
Satellos Bioscience has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its investigational therapy SAT-3247 for the...
Elixirgen and Nippon Shinyaku Partner on Full-Length Dystrophin Therapy for Duchenne
Elixirgen Therapeutics has announced a strategic option agreement with Nippon Shinyaku for the development and potential global commercialization of EXG-7001, an investigational full-length dystrophin...
REGENXBIO Completes RGX-202 Confirmatory Study for Duchenne Muscular Dystrophy
REGENXBIO has announced the completion of patient dosing in the confirmatory study of RGX-202, its investigational gene therapy for Duchenne Muscular Dystrophy (DMD). This...